Gerkens, S <br/><br/>
A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.  [electronic resource] 

 -  Journal of viral hepatitis  Aug 2007 
 - 523-36 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1352-0504 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2893.2006.00831.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--economics<br/>Belgium<br/>Computer Simulation<br/>Cost-Benefit Analysis<br/>Drug Costs<br/>Hepacivirus--growth & development<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--economics<br/>Markov Chains<br/>Middle Aged<br/>Models, Econometric<br/>Polyethylene Glycols--economics<br/>Quality-Adjusted Life Years<br/>Recombinant Proteins<br/>Ribavirin--economics